Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data
- 1 May 2017
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 77, 99-108
- https://doi.org/10.1016/j.ejca.2017.03.002
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancerMedicine, 2016
- Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysisEuropean Urology, 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Androgen Deprivation Therapy for Prostate Cancer Is Associated with Cardiovascular Morbidity and Mortality: A Meta-Analysis of Population-Based Observational StudiesPLOS ONE, 2014
- Androgen deprivation therapy complicationsEndocrine-Related Cancer, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2013
- Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?British Journal of Cancer, 2012
- Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate CancerJAMA, 2011
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular RiskCirculation, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006